Press Releases

2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

2012
Dec 2012 | Download as pdf

Sandalwood giant can smell big dollars in warts more

Dec 2012 | Download as pdf

ViroXis Corporation Announces expanded board of directors and advisors more

Dec 2012 | Download as pdf

ITClamp Hemorrhage Control System from Innovative Trauma Care more

Dec 2012 | Download as pdf

ViroXis Corporation Initiates Phase II Clinical Trial of Novel Botanical Topical Treatment for HPV Skin Warts more

Oct 2012 | Download as pdf

Vidacare Corp. aims to ease that pain with the OnControl Bone Marrow System. The Bronze winner of The Wall Street Journal's Technology Innovation Awards, and winner of the Medical-Devices category, the product allows doctors to more quickly and precisely take samples from inside the bone more

Oct 2012 | Download as pdf

DNAtrix, Inc., the Houston-based biotechnology company developing targeted adenovirus-based oncolytic virus products, announced today a merger with VectorLogics, Inc. more

Sept 2012 | Download as pdf

Innovative Trauma Care (ITC) has received regulatory approval from Health Canada for commercial sale of its first product, the IT Clamp™ more

Sept 2012 | Download as pdf

BiO2 Medical, Inc and R&D and manufacturing operations in Golden, Colorado, has recently secured $12M in Series C funding more

Sept 2012 | Download as pdf

ENTrigue Surgical Announces Sinus Surgery Collaboration with fiagon GmbH more

June 2012 | Download as pdf

Soluble Therapeutics, Inc. Awarded ~$1MM NIH Grant for Continued Development of the HSC Technology for Protein Formulation more

June 2012 | Download as pdf

Vidacare Corporation Creates New Medical Director of Clinical Affairs Position for Intraosseous Vascular Access Division more

May 2012 | Download as pdf

BiO2 Medical Granted CE Mark for the Angel™ Catheter, the First IVC Filter with a Prophylactic Use Indication more

April 2012 | Download as pdf

NMP Neuwirth Medical Products GmbH signs an exclusive distribution partnership for the Ventera, MediENT, ENTact, Synaero, and SerpENT in Germany

March 2012 | Download as pdf

ENTrigue Surgical participates in the first Global Update on FESS, The Sinuses, and The Nose in Vienna, Austria

March 2012 | Download as pdf

BiO2 Medical Announces First in Man Clinical Study.

BiO2 Medical, Inc., a Texas based medical device manufacturer with manufacturing operations in Golden, Colorado, is proud to announce the first in man clinical study for the Angel™ Catheter. The clinical study is being conducted under IRB approval at two medical centers in Medellin, Colombia, Clinica Las Americas, and Hospital Pablo Tobon Uribe. As of today, eight critically ill patients have been enrolled in the study.

Dr. Cadavid and Dr. Gil, the principal investigators in the first in man clinical study, commented on the ease of bedside insertion of the Angel™ Catheter in a procedure that resembles a routine central venous catheter placement. Both principal investigators feel that the Angel ™ Catheter fills an important clinical need for an Inferior Vena Cava filter designed for use in critically ill patients at high risk of pulmonary embolism (PE).

Dr. John A. Kaufman from the Dotter Interventional Institute and a member of BiO2 Medical's clinical advisory board said, "This marks an important advance in the management of critically ill patients everywhere. The ability to protect from pulmonary embolism and resuscitate with one device is unique."

This important milestone for the company will provide vital data regarding the safety of the Angel™ Catheter in a clinical setting, which will be instrumental in facilitating clinical adoption of the device. BiO2 Medical has been working closely with Pharmaceutical Product Development, Inc. (PPD), a contract research organization (CRO) that provides expertise in clinical development, management, and post approval services, in the design and execution of this first in man clinical study.

BiO2 Medical's Chairman and Chief Executive Officer, Christopher E. Banas, commented on the initiation of the clinical study, "We are proud to be providing a lifesaving technology for critically ill patients at risk of PE, and this study demonstrates that this device is safe for use."

For more information regarding BiO2 Medical, and the Angel™ Catheter please visit www.bio2medical.com back

March 2012 | Download as pdf

BiO2 Medical Secures Series B Round Funding more

Jan 2012 | Download as pdf

Study Finds Intraosseous Infusion is Equivalent to Intravenous Infusion During Therapeutic Hypothermia more

Jan 2012 | Download as pdf

Vidacare Corporation to Sponsor 2012 British Journal of Nursing Haematology Award Category more